Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
06 2019
Historique:
received: 14 04 2018
revised: 27 01 2019
accepted: 30 01 2019
pubmed: 6 2 2019
medline: 14 4 2020
entrez: 6 2 2019
Statut: ppublish

Résumé

We present an evolutionary analysis of the relative time of genetic events underlying tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using multiregional whole-exome sequencing. We timed bladder cancer drivers, mutational signatures, ploidy and copy number alterations, provided evidence for kataegis and correlated alterations with tumour areas and histological phenotypes. We found that: (1) heterogeneous tumour areas/phenotypes had distinct driver mutations, (2) papillary-invasive tumours divided early into two parallel evolving branches and (3) parallel evolution of subclonal driver mutations occurred. APOBEC mutational signatures were found to be very early events, active in carcinoma in situ, and often remained a dominant source of mutations throughout tumour evolution. Genetic progression from carcinoma in situ followed driver mutations in NA13/FAT1, ZBTB7B or EP300/USP28/KMT2D. Our results point towards a more diverse mutational trajectory of bladder tumorigenesis and underpin the importance of timing of mutational processes and clonal architecture in bladder cancer as important aspects for successful prognostication and therapy. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Identifiants

pubmed: 30719704
doi: 10.1002/path.5250
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

230-242

Subventions

Organisme : Cancer Research UK
ID : A19771
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Auteurs

Timon Heide (T)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Angela Maurer (A)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Monika Eipel (M)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Katrin Knoll (K)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Mirja Geelvink (M)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Juergen Veeck (J)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Ruth Knuechel (R)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Julius van Essen (J)

Department of Urology, University Hospital RWTH Aachen University, Germany.

Robert Stoehr (R)

Institute of Pathology University Erlangen-Nuernberg, Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology University Erlangen-Nuernberg, Erlangen, Germany.

Janine Altmueller (J)

Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.

Trevor A Graham (TA)

Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Nadine T Gaisa (NT)

Institute of Pathology RWTH Aachen University, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH